Given the diverse role of cytokines such as IL-2 and IFN-γ in the GBM pathogenesis, therapeutics targeting the YY1-mediated downregulation of these cytokines may be beneficial in restoring immune balance and function. Here, IFNG is linked to glioblastoma.